236 related articles for article (PubMed ID: 2908528)
1. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
2. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
3. Effect of heptakis (2,6-0-dimethyl)beta-cyclodextrin on cell growth and the production of pertussis toxin and filamentous hemagglutinin in Bordetella pertussis.
Suzuki Y; Imaizumi A; Ginnaga A; Sato H; Sato Y
Dev Biol Stand; 1985; 61():89-92. PubMed ID: 2872134
[TBL] [Abstract][Full Text] [Related]
4. Overview of currently available Japanese acellular pertussis vaccines and future problems.
Kamiya H; Nii R
Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
[TBL] [Abstract][Full Text] [Related]
5. Japanese clinical trials with Takeda acellular pertussis vaccine.
Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
7. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
8. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
9. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
10. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
[TBL] [Abstract][Full Text] [Related]
11. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
12. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
Sato Y; Sato H
Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
[TBL] [Abstract][Full Text] [Related]
13. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
14. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
15. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
16. A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.
Christie CD; Garrison KM; Kiely L; Gupta RK; Heubi J; Marchant CD
Clin Infect Dis; 2001 Oct; 33(7):997-1003. PubMed ID: 11528571
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
18. The purification and characterization of an acellular pertussis vaccine.
Chazono M; Yoshida I; Konobe T; Fukai K
J Biol Stand; 1988 Apr; 16(2):83-9. PubMed ID: 2897370
[TBL] [Abstract][Full Text] [Related]
19. Further evaluation of the pertussis component vaccine produced by apoceruloplasmin affinity chromatography.
Ginnaga A; Morokuma K; Furukawa S; Shigaki T; Katsuki N; Aihara K; Oka T; Sakoh M; Tamura C; Imaizumi A
Dev Biol Stand; 1991; 73():233-41. PubMed ID: 1778315
[TBL] [Abstract][Full Text] [Related]
20. Serological responses to infection with B. pertussis.
Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
